PortalPublikationen18F-FDG PET/CT for Detection of Leukemic Transformation in M...

18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis

Standard

18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. / Derlin, Thorsten; Clauditz, Till Sebastian; Kröger, Nicolaus.

in: CLIN NUCL MED, Jahrgang 40, Nr. 6, 06.2015, S. 521-2.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Derlin, T, Clauditz, TS & Kröger, N 2015, '18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis', CLIN NUCL MED, Jg. 40, Nr. 6, S. 521-2. https://doi.org/10.1097/RLU.0000000000000728

APA

Derlin, T., Clauditz, T. S., & Kröger, N. (2015). 18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. CLIN NUCL MED, 40(6), 521-2. https://doi.org/10.1097/RLU.0000000000000728

Vancouver

Derlin T, Clauditz TS, Kröger N. 18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. CLIN NUCL MED. 2015 Jun;40(6):521-2. https://doi.org/10.1097/RLU.0000000000000728

Bibtex

@article{0457555bb7634089974713c8715a623e,
title = "18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis",
abstract = "Myelofibrosis is a rare clonal hematopoietic stem cell disorder characterized by chronic myeloproliferation, atypical megakaryocytic hyperplasia, and potential leukemic transformation. We report a case of leukemic transformation detected by F-FDG PET/CT. A 56-year-old woman with myelofibrosis and newly diagnosed space-occupying lesion of the chest wall underwent whole-body PET/CT for further evaluation. F-FDG PET demonstrated marked tracer uptake within that lesion. Histopathological evaluation revealed myeloid sarcoma evidencing leukemic transformation. F-FDG PET/CT is a valuable tool-enabling sensitive detection of leukemic transformation in myelofibrosis, particularly in case of extramedullary organ involvement.",
author = "Thorsten Derlin and Clauditz, {Till Sebastian} and Nicolaus Kr{\"o}ger",
year = "2015",
month = jun,
doi = "10.1097/RLU.0000000000000728",
language = "English",
volume = "40",
pages = "521--2",
journal = "CLIN NUCL MED",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - 18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis

AU - Derlin, Thorsten

AU - Clauditz, Till Sebastian

AU - Kröger, Nicolaus

PY - 2015/6

Y1 - 2015/6

N2 - Myelofibrosis is a rare clonal hematopoietic stem cell disorder characterized by chronic myeloproliferation, atypical megakaryocytic hyperplasia, and potential leukemic transformation. We report a case of leukemic transformation detected by F-FDG PET/CT. A 56-year-old woman with myelofibrosis and newly diagnosed space-occupying lesion of the chest wall underwent whole-body PET/CT for further evaluation. F-FDG PET demonstrated marked tracer uptake within that lesion. Histopathological evaluation revealed myeloid sarcoma evidencing leukemic transformation. F-FDG PET/CT is a valuable tool-enabling sensitive detection of leukemic transformation in myelofibrosis, particularly in case of extramedullary organ involvement.

AB - Myelofibrosis is a rare clonal hematopoietic stem cell disorder characterized by chronic myeloproliferation, atypical megakaryocytic hyperplasia, and potential leukemic transformation. We report a case of leukemic transformation detected by F-FDG PET/CT. A 56-year-old woman with myelofibrosis and newly diagnosed space-occupying lesion of the chest wall underwent whole-body PET/CT for further evaluation. F-FDG PET demonstrated marked tracer uptake within that lesion. Histopathological evaluation revealed myeloid sarcoma evidencing leukemic transformation. F-FDG PET/CT is a valuable tool-enabling sensitive detection of leukemic transformation in myelofibrosis, particularly in case of extramedullary organ involvement.

U2 - 10.1097/RLU.0000000000000728

DO - 10.1097/RLU.0000000000000728

M3 - SCORING: Journal article

C2 - 25674874

VL - 40

SP - 521

EP - 522

JO - CLIN NUCL MED

JF - CLIN NUCL MED

SN - 0363-9762

IS - 6

ER -